^
Association details:
Biomarker:No biomarker
Cancer:Squamous Cell Carcinoma of Head and Neck
Regimen:TPF (5-fluorouracil + cisplatin + docetaxel)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
10/11/2019
Excerpt:
Docetaxel Injection is a microtubule inhibitor indicated for...Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN.
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Pan-Asian adaptation of the EHNSeESMOeESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

Excerpt:
Recommendation 3: Treatment...induction chemotherapy with TPF (up to three courses according to response) followed by RT alone is a validated treatment option [I, A].